Cellectar Biosciences, Inc. (CLRB) to Release Quarterly Earnings on Thursday
Cellectar Biosciences, Inc. (NASDAQ:CLRB) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, analysts expect Cellectar Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Cellectar Biosciences, Inc. (CLRB) opened at $1.54 on Tuesday. Cellectar Biosciences, Inc. has a one year low of $1.12 and a one year high of $3.07.
CLRB has been the subject of several research analyst reports. Zacks Investment Research raised Cellectar Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
TRADEMARK VIOLATION WARNING: “Cellectar Biosciences, Inc. (CLRB) to Release Quarterly Earnings on Thursday” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/07/cellectar-biosciences-inc-clrb-to-release-quarterly-earnings-on-thursday.html.
A hedge fund recently raised its stake in Cellectar Biosciences stock. Vanguard Group Inc. boosted its position in Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 31.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,208 shares of the biopharmaceutical company’s stock after purchasing an additional 35,482 shares during the period. Vanguard Group Inc. owned about 1.09% of Cellectar Biosciences worth $240,000 as of its most recent SEC filing. 2.35% of the stock is owned by institutional investors and hedge funds.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Stock Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related stocks with our FREE daily email newsletter.